Unlocking the secrets of cytotoxic granule proteins.
Cytotoxic lymphocytes largely comprise CD8(+) cytotoxic T cells and natural killer cells and form the major defense of higher organisms against virus-infected and transformed cells. A key function of cytotoxic lymphocytes is to detect and eliminate potentially harmful cells by inducing them to undergo apoptosis. This is achieved through two principal pathways, both of which require direct but transient contact between the killer cell and its target. The first, involving ligation of TNF receptor-like molecules such as Fas/CD95 by their cognate ligands, results in mobilization of conventional, programmed cell-death pathways centered on activation of pro-apoptotic caspases. This review concentrates on the second pathway, in which the toxic contents of secretory vesicles of the cytotoxic lymphocyte are secreted toward the target cell, and some toxins penetrate into the target cell cytoplasm and nucleus. In addition to invoking a powerful stimulus to caspase activation, this "granule-exocytosis mechanism" provides a variety of additional strategies for overcoming inhibitors of the caspase cascade that may be elaborated by viruses. The key molecular players in this process are the pore-forming protein perforin and a family of granule-bound serine proteases or granzymes. The molecular functions of perforin and granzymes are under intense investigation in many laboratories including our own, and recent advances will be discussed. In addition, this review discusses the evidence pointing to the importance of perforin and granzyme function in pathophysiological situations as diverse as infection with intracellular pathogens, graft versus host disease, susceptibility to transplantable and spontaneous malignancies, lymphoid homeostasis, and the tendency to auto-immune diseases.
Smyth
M J
MJ
Cancer Immunology Division, Trescowthick Laboratories, Peter MacCallum Cancer Institute, Melbourne, Australia. m.smyth@pmci.unimelb.edu.au
Kelly
J M
JM
Sutton
V R
VR
Davis
J E
JE
Browne
K A
KA
Sayers
T J
TJ
Trapani
J A
JA
D000818:Animals; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology / Q000378:metabolism / Q000502:physiology*; D002135:Calcium-Binding Proteins / Q000276:immunology / Q000378:metabolism / Q000502:physiology*; D037282:Calreticulin; D018925:Chemokines / Q000276:immunology / Q000378:metabolism / Q000502:physiology*; D003594:Cytoplasmic Granules / Q000276:immunology / Q000378:metabolism; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology / Q000378:metabolism; D008562:Membrane Glycoproteins / Q000276:immunology / Q000378:metabolism / Q000502:physiology*; D054353:Perforin; D052899:Pore Forming Cytotoxic Proteins; D012261:Ribonucleoproteins / Q000276:immunology / Q000378:metabolism / Q000502:physiology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology / Q000378:metabolism
D000945:Antigens, Differentiation, T-Lymphocyte; D002135:Calcium-Binding Proteins; D037282:Calreticulin; D018925:Chemokines; C075005:GNLY protein, human; D008562:Membrane Glycoproteins; D052899:Pore Forming Cytotoxic Proteins; D012261:Ribonucleoproteins; D054353:Perforin